What Сульперазон treats: Main Uses and Benefits

Сульперазон (Cefoperazone/Sulbactam) is commonly used in situations involving certain distressing symptoms of bacterial infections caused by susceptible organisms. This antibiotic combination is considered relevant in clinical settings marked by multi-drug resistant (MDR) bacteria, particularly in infections acquired in the hospital setting. Its use provides supportive relief that helps patients cope more steadily with symptom fluctuations related to deep-seated tissue inflammation and systemic distress.

It is applied across therapeutic domains where additional symptomatic support is needed to address acute and severe infectious diseases. These conditions include infections presenting with severe systemic discomfort, peritonitis, infections of the bones and joints, and complicated urinary tract and pelvic infections. Its use provides symptomatic relief and helps maintain a sense of stability by supporting the management of conditions involving inflammatory or irritative processes. This medicine is applied in scenarios where symptoms create noticeable physiological strain and **functional stability becomes affected.

---

Quick Fact: Symptomatic Context This medication is generally used to address acute systemic symptoms (like high fever and chills) and intense localized discomfort (such as severe abdominal pain or joint swelling) arising from complicated bacterial infections.

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults, older adults, and the general pediatric population are eligible for use under established conditions.

Populations for whom use is contraindicated:

• Patients with a confirmed history of allergy (hypersensitivity) to penicillins.
• Patients with a known allergy to sulbactam, cefoperazone, or any other cephalosporin-class antibiotics.

Age-related eligibility rules: While use is permitted in adults and older adults, official labeling notes that the medicine has not been extensively studied in premature infants or neonates, necessitating specific clinical evaluation before use.

Condition-specific eligibility rules: Eligibility is restricted for patients with marked decrease in renal function (Creatinine clearance lt 30 mL/min) and those with severe hepatic disease or biliary obstruction. Conditional use also applies to patients with concurrent hepatic and renal impairment, and to those at risk of Vitamin K deficiency.

Pregnancy and lactation eligibility status (if explicitly documented): Pregnancy: Use is permitted only if clearly needed. Lactation: Caution must be exercised, as the medicine is excreted into human milk.

---

Connection to the Overall Eligibility Profile

Regulatory documentation defines who can use this medicine by establishing a clear structure of absolute exclusion and conditional use. Eligibility is primarily structured around prohibiting use due to immunological risk (hypersensitivity) and restricting use based on physiological function (liver and kidney health) to manage accumulation risks defined in official labeling.

Interactions with other medicines and products

The official regulatory documents for Сульперазон (Cefoperazone/Sulbactam) detail several specific interaction patterns that impose restrictions or require specific administration procedures. The interaction profile is structured around co-administration risks, physical incompatibilities, and substance avoidance.

Drug-Drug Interactions (Pharmacodynamic & Exposure-Altering)

• Oral Anticoagulants (e.g., Warfarin): Co-administration may result in a pharmacodynamic interaction that increases the risk of bleeding and marked hypoprothrombinemia.
• Aminoglycosides (e.g., Gentamicin): Concomitant use is associated with a documented risk of increased nephrotoxicity. Additionally, to prevent in vitro physical incompatibility, these agents must not be mixed directly. When co-administered, they must be administered separately, and the intravenous infusion line requires mandatory flushing between doses.

Drug-Substance and Population-Specific Interactions

• Alcohol (Ethanol): Ingestion of alcohol during treatment, and for a period extending up to five days after the final dose, is explicitly restricted due to the potential for a Disulfiram-like reaction (e.g., flushing, tachycardia).
• Hepatic and Renal Impairment: In cases where hepatic dysfunction co-exists with renal impairment, the regulatory profile notes that the half-life of Cefoperazone may be prolonged. This pharmacokinetic change increases the overall exposure to the medicine, necessitating closer patient monitoring.

The core mechanism of Cefoperazone involves the covalent binding and irreversible inhibition of essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). This molecular action immediately halts the final step of peptidoglycan cross-linking necessary for assembling the bacterial cell wall. The resulting structural failure leads to the activation of bacterial autolytic enzymes, causing rapid cell lysis.

The Sulbactam component functions as a complementary mechanistic step, targeting bacterial beta-lactamase enzymes. Sulbactam acts as a suicide substrate, irreversibly inactivating these beta-lactamase enzymes that would otherwise hydrolyze and destroy Cefoperazone. This synergistic protection maintains the cell wall-disrupting activity of Cefoperazone against strains that produce beta-lactamase enzymes, thereby extending the range of organisms susceptible to the cell wall-disruption mechanism. Sulbactam also contributes directly to cell disruption via its intrinsic PBP inhibition in specific pathogens like Acinetobacter.

How to Use Сульперазон: Official Administration Guidelines

Сульперазон (Cefoperazone/Sulbactam) is provided as a sterile lyophilisate (dry powder) for solution for injection, necessitating administration by a healthcare professional. The official usage instructions dictate the specific route, preparation, and dose adjustments required for proper use.

---

Administration Scope

Feature	Official Guideline
Route of Administration	Intravenous (IV) via infusion or direct bolus injection, or Intramuscular (IM) injection.
Adult Standard Dose	2 g to 4 g total Sulbactam/Cefoperazone daily in equally divided doses. For severe cases, up to 8 g total IV may be used.
Dosing Frequency	Administered every 12 hours (q12h) for adults. Pediatric doses are given every 6 to 12 hours.

---

Procedural and Adjustment Requirements

Proper use requires specific technical steps and population-based adjustments:

• Preparation: The powder must be reconstituted with appropriate solutions, such as 0.9% Sodium Chloride or Sterile Water for Injection, and is then typically further diluted for infusion.
• IV Timing: When administered as a direct IV injection (bolus), the solution must be delivered over a minimum of 3 minutes.
• Maximum Limits: The maximum recommended daily dosage for the Sulbactam component is 4 g for adults.
• Renal Impairment: Dosage adjustments are mandatory in patients with creatinine clearance < 30 mL/min to control the clearance of Sulbactam. For example, the maximum daily Sulbactam dose is restricted to 2 g for CrCl 15 - 30 mL/min.
• Dialysis: For patients undergoing hemodialysis, dosing should be precisely scheduled to follow the dialysis period.

This structured approach ensures the drug's administration is performed consistently within the established parameters.

Research evidence / Overview of studies for Сульперазон (Cefoperazone/Sulbactam)

Evidence for Use in Major Infections

Research into complicated intra-abdominal infections and severe pneumonia primarily relies on systematic reviews and meta-analyses, which incorporate data from multiple Randomized Controlled Trials (RCTs). These studies were designed to compare the combination drug with other antibiotic regimens, examining key outcomes related to systemic imbalance, such as the overall rate of measured clinical status outcomes and mortality metrics. For severe lung infections, research also included Randomized Noninferiority Trials designed to explore the relationship between the drug’s measured outcomes and those of a comparator antibiotic in critically ill patients.

Evidence for Use in Resistant Pathogens and Specific Contexts

Evidence related to difficult-to-treat, Multi-Drug Resistant (MDR) bacteria, like Acinetobacter baumannii, is mainly derived from Observational Studies and retrospective data. These studies focus on tracking mortality outcomes in high-risk populations. For the specific clinical context of febrile neutropenia (low white blood cell count), the evidence base relies on systematic reviews of multiple RCTs. This research measured clinical status outcomes without requiring a change in the initial antibiotic regimen, providing insight into short-term changes during empiric therapy.

Key Limitations and Areas of Uncertainty

Across the evidence landscape, a consistent limitation is that the majority of the research focuses on the acute treatment period, meaning that long-term effects are not fully established regarding the duration of observed responses. For infections caused by MDR pathogens, certainty remains low because high-quality, large-scale RCTs are lacking, and the research relies heavily on non-randomized data. Findings describe group patterns, and research does not determine whether an individual will respond similarly to the group outcomes described in the study results.

Key Studies & References

1. Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study
2. Sulbactam Sodium/Cefoperazone Sodium Trade Name: SULPERAZON CDS (Official Product Information)

Common questions about Сульперазон (FAQ)

Q: Does the 'Sulbactam' component of Сульперазон also fight bacteria?

A: While Sulbactam is included mainly to protect the Cefoperazone antibiotic from being destroyed, official documents indicate it does have some independent antibacterial activity. This activity is considered weak overall but has been specifically noted against certain types of bacteria, such as Acinetobacter.

Q: Can Сульперазон treat stomach or intra-abdominal infections?

A: Yes, official product information states that this medicine is indicated for treating a variety of intra-abdominal infections. This includes conditions such as peritonitis and cholecystitis, when they are caused by organisms that are susceptible to the drug. The drug is indicated for serious infections, which is a factor in its typical use.

Q: Is Сульперазон a drug used primarily in hospital or clinical settings?

A: According to the official product information, the drug is formulated as a powder for injection and must be administered by a healthcare professional via an IV or IM route. Since it is reserved for serious infections and requires professional preparation, its use is typically confined to clinical or hospital settings.

Q: What is the expected length of time for a full course of treatment with Сульперазон?

A: The full length of treatment is not a standardized number and depends entirely on the type and severity of the infection being treated. While some less complicated infections may be treated quickly, official guidelines indicate that courses for more severe or complicated infections may last from 14 to 21 days.

Q: What is the general guidance if a dose of Сульперазон is missed or delayed?

A: The regulatory safety advice states that the prescribing healthcare professional should be contacted immediately if a dose is missed or delayed. The advice emphasizes that doses should not be skipped and that the full, prescribed course should be completed.

Q: Is it necessary to finish the entire prescribed course of Сульперазон even if symptoms resolve?

A: Official patient advice emphasizes the necessity of finishing the entire course of treatment as prescribed, even if symptoms improve. This is essential, as stopping therapy early can increase the risk of developing drug-resistant bacteria.

Q: Can Сульперазон affect blood counts or cause bleeding issues?

A: Studies indicate that the drug can affect blood cell counts, which may show up as abnormalities like leukopenia or eosinophilia. Additionally, the drug has been associated with an increased risk of bleeding (hypoprothrombinemia). Hypoprothrombinemia has sometimes been managed with Vitamin K administration, according to official information.

Q: How should one monitor for potential signs of an adverse reaction to Сульперазон?

A: Official regulatory safety information indicates that immediate medical attention is necessary if signs of a serious allergic reaction occur, such as a severe rash, swelling, or difficulty breathing. It is important to be aware of and report persistent side effects, such as severe or bloody diarrhea.

Q: Is it true that Сульперазон can cause Vitamin K deficiency?

A: Official regulatory label information notes that a Vitamin K deficiency, which can lead to a bleeding disorder known as coagulopathy, has been observed in some patients treated with this drug.

Q: Does Сульперазон commonly cause discomfort, pain, or swelling at the injection site?

A: Yes, local reactions have been reported in regulatory documents. This includes pain at the injection site following an intramuscular injection and phlebitis (inflammation of the vein) after an intravenous infusion.

Q: How often do serious side effects occur with Сульперазон?

A: Serious reactions, such as anaphylaxis (severe allergic shock), are typically reported in the post-marketing setting. Many severe side effects are classified as Frequency Not Known by regulators because their exact rate of occurrence cannot be reliably estimated from available clinical trial data.

Q: Can Сульперазон cause seizures?

A: Official product information indicates that seizures may occur, particularly if the drug is administered in excessively high doses. This risk is specifically noted for patients with kidney impairment, where drug accumulation can occur.

Q: Can children or infants be treated with Сульперазон?

A: Yes, the drug is approved for use in the pediatric population, but use in this population requires specialized dosing. Specific caution is noted regarding use in neonates and premature infants, especially in the first week of life, as this population has not been extensively studied.

Q: Are there age-related cautions for elderly patients using Сульперазон?

A: Regulatory information indicates that older adults are eligible to receive this medicine under the established conditions for use. No specific, unique cautions or restrictions for this drug are typically detailed for the elderly population beyond those applicable to adults in general.

Q: Does Сульперазон affect the results of any common laboratory tests?

A: Yes, the official side effect profile includes reports of transient elevations in liver function tests (LFTs), such as serum transaminases. These changes are typically temporary and often return to normal levels after therapy is completed. Monitoring of other laboratory tests may be necessary as part of clinical oversight.

Q: What is the overall body of evidence supporting the use of Сульперазон?

A: Studies and official product information confirm the drug's efficacy for treating serious bacterial infections, including those in the respiratory, abdominal, and pelvic regions. The overall body of evidence is supported by various clinical studies, including Randomized Controlled Trials, which compare its outcomes to other standard antibiotic regimens.

Q: Does Сульперазон treat infections that are resistant to other antibiotics?

A: The drug is specifically designed to address a major mechanism of resistance by combining an antibiotic with Sulbactam, a protective agent. This combination is effective against bacterial strains that produce beta-lactamase enzymes, which would otherwise destroy the Cefoperazone antibiotic.

Q: Is Сульперазон effective for infections in the skin and soft tissues?

A: Yes, according to the official product indications, the drug is approved for the treatment of Skin and Soft Tissue Infections. This use is restricted to cases caused by bacteria that are susceptible to this specific combination medicine.

Q: Is Сульперазон used for serious, life-threatening infections?

A: Official product information indicates that this medicine is used for the treatment of serious infections. The possibility of increasing the daily dose for severe or refractory cases, including conditions like septicemia and meningitis, further suggests its use in critical scenarios.

Q: Does Сульперазон work against Gram-negative bacteria?

A: The Cefoperazone component is classified as a third-generation cephalosporin, which is known for its activity against a wide range of bacteria. Official regulatory sources confirm that this includes strong activity against Gram-negative bacteria.

Q: Can Сульперазон treat infections in the female genital tract?

A: Yes, official product indications specifically list the treatment of infections of the genital tract. This includes conditions such as endometritis and Pelvic Inflammatory Disease (PID).

Q: What information is available if an injection of Сульперазон causes local pain?

A: Local side effects have been reported in the post-marketing setting. This includes local pain following an intramuscular injection and phlebitis, or inflammation of the vein, following an intravenous infusion.

Q: Are allergic reactions to Сульперазон common?

A: Hypersensitivity reactions, such as skin rashes, are considered a common side effect and may require the cessation of therapy. However, serious allergic reactions like anaphylactic shock are rarer events reported in the post-marketing setting.

Q: Is severe diarrhea a known side effect of Сульперазон?

A: Diarrhea is the most frequent gastrointestinal side effect noted in the drug's profile. Regulatory documentation has noted cases of Clostridium difficile infection in some patients, which is a condition that can cause severe, potentially life-threatening diarrhea. Severe or persistent diarrhea is a symptom that warrants clinical review.

Q: What is the risk of a superinfection (like thrush) when using Сульперазон?

A: Official safety warnings common to broad-spectrum antibiotics advise that treatment may result in the overgrowth of non-susceptible organisms. The regulatory precaution is that patients receiving therapy should be monitored for the emergence of new infections (superinfections).

Q: Is it true that people with a history of digestive issues like colitis need extra caution with Сульперазон?

A: Yes, regulatory warnings identify a need for caution when the drug is used in patients with a known history of gastrointestinal disease, such as colitis. This conditional use is noted because of the drug's potential for gastrointestinal side effects.

Storage and Disposal Requirements for Sulperazon (Cefoperazone/Sulbactam)

The storage and disposal instructions for Sulperazon (lyophilisate for injection) are defined by official regulatory documentation to maintain product stability and safety.

Storage Conditions

Product State	Required Condition
Unopened Dry Powder	Store at controlled room temperature (20 C to 25 C). Must be protected from light and excessive moisture in the original packaging.
Reconstituted Solution	Stability is diluent-dependent. Solutions are typically stable for 24 hours at room temperature or longer when refrigerated (2 C to 8 C).

All forms of the medicine must be stored out of the sight and reach of children.

Disposal

Unused or expired Sulperazon must not be disposed of in wastewater or general household trash. Disposal must adhere to local pharmaceutical waste regulations. The official method for disposal is utilizing a drug take-back program or an authorized collection site.